Home › Calculator › VSTM Dividend Calculator 2026
VSTM Dividend DRIP Calculator 2026
30.40% YieldHealthcareVerastem, Inc. · NASDAQ
Price: $6.58 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When VSTM pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your VSTM snowball 📈
$10,000 in VSTM → $23621899.17M in 10 years · $1,962,187,304,509.85/month
About Verastem, Inc. (VSTM) — Dividend Analysis 2026
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
Compare VSTM with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full VSTM DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open VSTM position with:
🌍 VSTM Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold VSTM.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 30.40% | 27.60% | $3,040 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 25.84% | 23.04% | $2,584 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 24.32% | 21.52% | $2,432 / yr |
| 🇬🇧 UK ISA | 0% | 30.40% | 27.60% | $3,040 / yr |
| 🇬🇧 UK Taxable | 8.75% | 27.74% | 24.94% | $2,774 / yr |
| 🇨🇦 TFSA | 0% | 30.40% | 27.60% | $3,040 / yr |
| 🇨🇦 CA Taxable | 25% | 22.80% | 20.00% | $2,280 / yr |
| 🇦🇺 Super (pension) | 15% | 25.84% | 23.04% | $2,584 / yr |
| 🇦🇺 AU Taxable | 30% | 21.28% | 18.48% | $2,128 / yr |
| 🇩🇪 DE Taxable | 26.375% | 22.38% | 19.58% | $2,238 / yr |
| 🇫🇷 FR Taxable | 30% | 21.28% | 18.48% | $2,128 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 VSTM Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 VSTM Dividend Payment Schedule
VSTM pays quarterly — 4 times per year. Next ex-div: TBD.
📊 VSTM vs Healthcare Benchmarks
How VSTM compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for VSTM sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ VSTM Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-08-03 | 1,302 | $5.81 | $7.6K | ||
| Sale | 2026-06-22 | 20,871 | $4.18 | $87.2K | ||
| Sale | 2026-06-22 | 4,032 | $4.18 | $16.9K | ||
| Sale | 2026-06-22 | 57 | $4.13 | $235.00 | ||
| A-Award | 2026-05-21 | 108,000 | — | — | ||
| A-Award | 2026-05-21 | 36,000 | — | — | ||
| A-Award | 2026-05-21 | 36,000 | — | — | ||
| A-Award | 2026-05-21 | 36,000 | — | — | ||
| A-Award | 2026-05-21 | 36,000 | — | — | ||
| A-Award | 2026-05-21 | 36,000 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the VSTM dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Verastem, Inc. (VSTM) is currently trading at $6.58, 87% below its 52-week high. The current dividend yield is 30.40% based on an annual payout of $2.00 per share.
VSTM (Verastem, Inc.) — 30.40% Dividend Yield Analysis
Verastem, Inc. (VSTM) is a healthcare stock currently trading at $6.58 with a dividend yield of 30.40%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (30.40%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest VSTM News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.